Lannett Company Launches Fluphenazine HCl Tablets USP
2010年10月18日 - 9:00PM
ビジネスワイヤ(英語)
Lannett Company, Inc. (AMEX: LCI), a manufacturer of generic
pharmaceuticals, today announced that it has commenced shipping
Fluphenazine HCl Tablets USP, the generic equivalent of Prolixin®,
in 1 mg, 2.5 mg, 5 mg and 10 mg dosages. For the 12 months ended
September 2010, Fluphenazine HCl Tablets USP, 1 mg, 2.5 mg, 5 mg,
& 10 mg had U.S. sales of approximately $28 million at Average
Wholesale Price. Lannett acquired an FDA approved Abbreviated New
Drug Application (ANDA) for Fluphenazine HCl Tablets USP, in 1 mg,
2.5 mg, 5 mg and 10 mg dosages.
“To broaden our product offering and help offset the FDA
backlog, we augment our internal drug development efforts with
strategic alliances and product acquisitions,” said Arthur
Bedrosian, president and chief executive officer of Lannett.
“Fluphenazine represents our second product launch resulting from
an acquired ANDA. We continue to seek additional opportunities to
expand our portfolio through collaboration or the purchase of
complementary products.”
Fluphenazine HCl Tablets USP, 1 mg, 2.5 mg, 5 mg and 10 mg are
antipsychotic agents used in the treatment of schizophrenia and
other mental illnesses.
About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures,
packages, markets and distributes generic pharmaceutical products
for a wide range of indications. For more information, visit
Lannett Company’s website at www.lannett.com.
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Any such statements, including, but not limited to,
adding Fluphenazine HCl Tablets to the company’s growing product
offering and the successful commercialization of the product,
whether expressed or implied, are subject to risks and
uncertainties which can cause actual results to differ materially
from those currently anticipated due to a number of factors which
include, but are not limited to, the difficulty in predicting the
timing or outcome of FDA or other regulatory approvals or actions,
the ability to successfully commercialize products upon approval,
Lannett’s estimated or anticipated future financial results, future
inventory levels, future competition or pricing, future levels of
operating expenses, product development efforts or performance, and
other risk factors discussed in the company’s Form 10-K and other
documents filed with the Securities and Exchange Commission from
time to time. These forward-looking statements represent the
company's judgment as of the date of this news release. The company
disclaims any intent or obligation to update these forward-looking
statements.
London Clubs (AMEX:LCI)
過去 株価チャート
から 6 2024 まで 7 2024
London Clubs (AMEX:LCI)
過去 株価チャート
から 7 2023 まで 7 2024